Note: EPS may not be comparable

Medifast (NYSE: MED) reported Q4 EPS of $0.60, $0.12 better than the analyst estimate of $0.48. Revenue for the quarter came in at $78 million versus the consensus estimate of $73.43 million.

Fourth Quarter and Full Year Highlights:

• Medifast revenue of $78.0 million for the quarter and $301.6 million for the year
• OPTAVIA revenue of $68.6 million for the quarter and $256.6 million for the year
• Net income of $7.3 million for the quarter and $27.7 million for the year
• Earnings per diluted share of $0.60 for the quarter and $2.29 for the year

Outlook

The Company expects first quarter revenue to be in the range of $88.5 million to $91.5 million and earnings per diluted share to be in the range of $0.84 to $0.87. For the full year 2018, the Company expects revenue of $350 million to $360 million and earnings per diluted share of $3.15 to $3.25. The full year 2018 earnings guidance assumes a 22% to 23% effective tax rate.

GUIDANCE:

Medifast sees FY2018 EPS of $3.15-$3.25, versus the consensus of $2.75. Medifast sees FY2018 revenue of $350-360 million, versus the consensus of $327.33 million.

For earnings history and earnings-related data on Medifast (MED) click here.